Recent Advances in the Synthesis and Biomedical Applications of Heterocyclic NO-Donors

Leonid L. Fershtat * and Egor S. Zhilin

Laboratory of Nitrogen Compounds, N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prosp., 47, 119991 Moscow, Russia; es.zhilin@gmail.com
* Correspondence: fershtat@bk.ru

Abstract: Nitric oxide (NO) is a key signaling molecule that acts in various physiological processes such as cellular metabolism, vasodilation and transmission of nerve impulses. A wide number of vascular diseases as well as various immune and neurodegenerative disorders were found to be directly associated with a disruption of NO production in living organisms. These issues justify a constant search of novel NO-donors with improved pharmacokinetic profiles and prolonged action. In a series of known structural classes capable of NO release, heterocyclic NO-donors are of special importance due to their increased hydrolytic stability and low toxicity. It is no wonder that synthetic and biochemical investigations of heterocyclic NO-donors have emerged significantly in recent years. In this review, we summarized recent advances in the synthesis, reactivity and biomedical applications of promising heterocyclic NO-donors (furoxans, sydnone imines, pyridazine dioxides, azasydnones). The synthetic potential of each heterocyclic system along with biochemical mechanisms of action are emphasized.

Keywords: nitric oxide; heterocycles; sydnone imines; furoxans; pyridazine dioxides; azasydnones; pharmacologically-active compounds

1. Introduction

Nitric oxide (NO) (also known as an endothelium-derived relaxing factor) is an endogenous inorganic soluble gas produced in mammalians from L-arginine and molecular oxygen by the enzyme nitric oxide synthase (NOS) [1,2]. NO is one of the most versatile molecules in animal and human biology with diverse roles in both physiology and pathophysiology. NO exhibits vasodilating properties with anti-smooth muscle cell activity [3], inhibits platelet adhesion and aggregation [4] and has other anti-inflammatory properties [5]. In addition, NO is capable of neurotransmittance and neuromodulation due to its involvement in cerebral blood flow auto- and chemoregulation [6].

In 1998, Furchgott, Ignarro and Murad received a Nobel Prize in Physiology or Medicine “for their discoveries concerning nitric oxide as a signaling molecule in the cardiovascular system” [7–9]. Since then, researches on the biochemical roles of NO have grown rapidly. It was found that NO plays also an important role in a number of pathophysiological diseases, such as arthritis, atherosclerosis, cancer, diabetes and various degenerative neuronal diseases [10–12]. Different release patterns of NO by different NO donors can modulate angiogenesis differentially: it was shown that while the short term NO donors are primarily active to initiate the angiogenesis by inducing cellular migration and ring formation, long term NO donors define later stages of angiogenesis such as vessel maturation and neovascularization [13]. NO donor or overexpression of endothelial NO synthase fused to a green fluorescent protein (eNOS-GFP) has a protective effect against hypoxia-induced cellular deadhesion and greatly improves the redox balance by inhibiting the oxidative stress [14]. Ectopic release of NO stimulates the protection of the endothelium leaky and improves actin dynamics under hypoxia milieu in chick embryo extravascular models [15]. At the same time, overexpression of exogenous NO levels in chicken embryos...
may increase the cell migration and cell proliferation on the right-hand side of the heart resulting in the *situs inversus* which is referred to as a congenital condition comprising of the reversion of the major visceral organs from their normal positions [16]. Recently, regulation of nitrosative and oxidative stresses by NO and its influence on lung diseases and cardiogenesis were thoroughly reviewed [17,18]. No wonder, the discovery of such crucial and indispensable biochemical patterns of NO stimulated a search of prodrug candidates capable of NO release under physiological conditions [19–23]. Overall, the creation of efficient methodologies for the construction of novel NO-donor heterocyclic and acyclic systems became one of the rapidly developing fields in organic and medicinal chemistry.

Glyceryl trinitrate (GTN) is a well-known, approved and inexpensive NO-donor, which lowers blood pressure and increases heart rate. However, GTN suffers from various side effects, such as headache, difficult or labored breathing, dizziness, and also may induce nitrate tolerance upon continuous exposure [24]. A similar pharmacological profile matches other organic nitrate-based pharmacologically active substances (e.g., isosorbide dinitrate) [25], although their levels of NO release are quite different [26]. Aside from organic nitrates, other nitrogen–oxygen acyclic species were reported as NO-donors: C- or N-nitroso compounds, nitrosothiols, oximes, hydroxylamines, hydroxyurea and metal-nitrosyl complexes (sodium nitroprusside) [22]. However, in recent years, heterocyclic NO-donors emerged with special attention due to their hydrolytic stability, safer storage and absence of tolerance [22,23,27]. The progress made in the design, synthesis and biochemistry of heterocyclic NO-donors in the last decade unveiled an application potential of such organic nitrogen–oxygen molecular systems in medicinal chemistry and drug design.

Therefore, in this review, we summarized recent advances in the synthesis and reactivity of structurally diverse NO-donors incorporating nitrogen–oxygen-enriched heterocyclic scaffold: sydnone imines, furoxans, azasydnones and pyridazine dioxides (Figure 1). These heterocyclic subclasses were chosen due to an increased number of researches on their synthesis, functionalization and properties. Main trends in synthetic methodologies for each type of heterocycle are presented. NO-releasing properties, pharmacological activity and other biomedical applications along with an analysis of structure–property relationships are also considered.

![Figure 1. Structures of heterocyclic NO-donors presented in this review.](image_url)

2. Sydnone Imines

The 1,2,3-oxadiazol-3-ium-5-aminides, also known as sydnone imines, are referred to as mesoionic heterocycles and constitute a considerable part of exogenous nitric oxide donors [28]. Due to the ability of NO release, iminosydrones are of great interest in the development of novel pharmaceutical ingredients. The most prominent of them, for example, are Linsidomine, Molsidomine and Marsidomine (Figure 2) which have improved pharmacological profiles due to the presence of the saturated nitrogen heterocyclic subunit linked to the sydnone imine scaffold via NN bond.
At physiological and a more alkaline pH, sydnone imines undergo rapid nonenzymatic hydrolysis to form the ring-opened N-nitrosamine, which is stable at pH 7.4 under anaerobic conditions protected from light. Traces of oxygen promote oxidative conversion to a cation radical intermediate which releases NO (Scheme 1) [22]. Interestingly, irradiation with visible light can remarkably enhance the oxygen-dependent NO release from sydnone imines [29].

N^3-Substituted sydnone imines 1 can be synthesized according to a standard method [30,31] via nitrosation of the corresponding amino nitriles 2 followed by cyclization to the target mesoionic heterocycle (Scheme 2). However, the cyclization is reversible and possible ring cleavage occurs through several degradation pathways depending on the solvent and pH of the reaction media. Therefore, to obtain stable sydnone imines suitable for storage and applications, they are usually converted to salts 3 or exo-N-substituted derivatives 4 [32].

In general, there are two reactive centers in the sydnone imine cycle—C^4 and N^6 positions (for clarity, the numbering of atoms is shown in Scheme 2), both of which represent nucleophilic properties. However, the N^6 atom is much more nucleophilic, which allows for performing selective functionalization of the sydnone imine scaffold through a preliminary transformation of free iminosydnone base into N^6-derived substances followed by C^4 modification. Reactions of sydnone imines at the N^6 position afford a wide diversity of variously substituted amides. The synthesis of N^6-derived sydnone imines is usually based on an interaction of the corresponding iminosydnone with various carbonyl electrophiles. For example, N^6-tert-butoxycarbonylsydnone imines 5 were synthesized by acylation of sydnone imine hydrochlorides 6 with Boc_2O in the presence of a catalytic amount of 4-dimethylaminopyridine (DMAP) in mild conditions (Scheme 3) [33].
Scheme 3. Interaction of sydnone imine hydrochlorides with Boc₂O.

N⁶-Carbamoyl sydnone imines 7a,b bearing an acyloxy alkyl carbamate motif were reported [34] as ocular prodrugs and were prepared in moderate yields by an interaction of pharmaceutically relevant substances SIN-1 or SA-2 with pivaloxy anhydride 8 in the presence of hydroxybenzotriazole and pyridine (Scheme 4).

Scheme 4. Acylation of sydnone imines with pivaloxy anhydride 8.

The 4-nitrophenyl carbonate derivatives 9 may also be used as suitable acylating agents to incorporate carbohydrate motifs onto the sydnone imine scaffold. Using this method, a few examples of sydnone imine glycosyl carbamates 10 representing a new class of glycosidase-dependent NO donors were prepared (Scheme 5) [35].

Scheme 5. Synthesis of sydnone imine glycosyl carbamates 10.

Iminosydrones 11 bearing an oxycarbonyl moiety can also be synthesized using chloroformates instead of anhydrides to perform an acylation of the imine function (Scheme 6) [36].
A mild method for the synthesis of N⁶-α-haloacyl substituted sydnone imines 12 based on a treatment of parent mesoionic heterocycles with α-haloacyl chlorides was developed [37]. Compounds 12 were shown to be convenient intermediates for the preparation of a large variety of N⁶-α-amino- and N⁶-α-thio-substituted acyl sydnone imines 13 (Scheme 7).

An interaction of sydnone imine hydrochlorides with sulfonyl chlorides in basic media afforded N⁶-sulfonyl iminosydnones 14 which have a great potential in bioorthogonal click-and-release methodology (Scheme 8) [38,39].

A convenient methodology for the selective N⁶-exocyclic functionalization of sydnone imines involving the addition of a large variety of nucleophiles on carbonyl-imidazolium-activated iminosydnones 15 was developed [40]. Initial imidazolium derivatives 15 can be easily obtained in two steps from the corresponding sydnone imines on a multigram scale. Compounds 15 are bench-stable for several weeks at room temperature and react efficiently with diverse heteroatom nucleophiles to afford a library of functionalized sydnone imines 16 (Scheme 9) [40]. This method has a broad substrate scope and tolerates sensitive functional groups. Variety of alkyl- and aryl-substituted amines, alcohols and thiols undergo nucleophilic substitution to achieve corresponding N⁶-functionalized sydnone imines 16.
Scheme 9. Synthesis and reactivity of carbonyl-imidazolium activated iminosydnones 15.

A number of sydnone imine-based ureas and thioureas 17 were prepared by reaction of parent iminosydnones with the corresponding aromatic and aliphatic isocyanates or isothiocyanates (Scheme 10) [39].

Scheme 10. Synthesis of carbamoyl and thiocarbamoyl sydnone imines 17.

An interaction of sydnone imine hydrochlorides with substituted phosphinate or phosphonate chlorides in the presence of diisopropylethylamine (DIPEA) was shown to be a highly efficient method for the preparation of N<sup>6</sup>-phosphorylated iminosydnones 18 in good and high yields (Scheme 11) [41]. Gram-scale quantities of N<sup>6</sup>-phosphorous derivatives 18 can be easily synthesized enabling their wide utilization in organic synthesis.

Scheme 11. Preparation of N<sup>6</sup>-phosphorylated iminosydnones 18.

C<sup>4</sup>-Halogenation of iminosydnones bearing a protected N<sup>6</sup>-imine function is one of the simplest ways for the functionalization of the sydnone imine scaffold. Sydnone imines 19 selectively halogenated at C<sup>4</sup> position by treatment with N-bromosuccinimide
(NBS) or N-iodosuccinimide (NIS) to form 4-bromo- or 4-iodo derivatives 20 and 21, respectively [39,42]. Unfortunately, 4-chlorosydnone imines were not formed even in trace amounts upon utilization of N-chlorosuccinimide. Interestingly, debromination of bromosydnone imines 20 proceeds in high yields using NaBH₄ or Na₂SO₃ [19]. The 4-bromosydnone imines 20 undergo Suzuki coupling with styrylboronic acid, while 4-iodoiminosydnone 21 react with phenylacetylene through Sonogashira coupling (Scheme 12) [39].

![Scheme 12](image-url)

Scheme 12. Synthesis and reactivity of halogenated sydnone imines.

Numerous patterns of C⁴ sydnone imine functionalization involve a preliminary lithiation of the starting material with nBuLi or LiHDMS in THF. The resulting deprotonated C⁴-lithio derivatives 22 are stable at room temperature in solutions under an inert atmosphere for several weeks and form anionic N-heterocyclic carbenes (NHC) (Scheme 13) capable of reaction with various electrophiles [41,43,44]. Interaction of C⁴-lithiosydnone imines with MeCN-d₃ resulted in C⁴-deuterated mesionic in quantitative yield, while the same reaction did not occur in the case of free sydnone imine. Anionic iminosydnone NHC may be trapped in a form of gold or palladium complexes by a treatment with Ph₃PAuCl and (Ph₃P)₂PdCl₂, respectively. N₃-aryl and N₃-morpholinylsydnone imine carbene Pd complexes were tested as catalysts in Suzuki–Miyaura and Sonogashira–Hagihara cross-coupling reactions [45].

![Scheme 13](image-url)

Scheme 13. Lithiation of sydnone imines and NHC thereof.

Sydnone imine-based copper complex as intermediate in cross-coupling reaction with various organic halides in the presence of Pd(PPh₃)₄ was postulated (Scheme 14) [45].
addition of copper bromide to a solution of sydnone imine carbenoid 22 at \(-80^\circ C\) provides a deep-colored solution of C4-copper derivative 23, which is fairly stable even at room temperature.

![Scheme 14. Copper-mediated cross-coupling reaction of sydnone imines with organic halides.](image)

C4-lithiated iminosydnones 22 react with diphenylphosphine chloride leading to a formation of C4-phosphine substituted derivatives 24 bearing two diverse donor atoms [46]. Considering the resulting functionalized sydnone imines as hemilabile bidentate ligands they were converted to 5-membered palladium complex 25 through the reaction with PdCl2(MeCN)2 (Scheme 15). DFT calculations of charge distribution and X-ray diffraction analysis for this unusual palladium mesoionic ligand coordination were carried out [46].

![Scheme 15. Synthesis of phosphorus-functionalized sydnone imines.](image)

C4-Thioether and C4-selenoether derivatives 26 and 27, respectively, were prepared [45,47] via C4 carbon lithiation, interaction of carbenoids 22 with elemental sulfur or selenium followed by reaction with electrophiles such as alkyl and aryl halides (Scheme 16). Lithium thiolate intermediates proved to be unstable and decomposed quickly upon isolation or storage in solutions.
Scheme 16. Preparation of thioether and selenoether sydnone imines.

C4-Lithiated iminosydnone 22 add to non-enolizable carbonyl compounds to form corresponding secondary alcohols 28 (Scheme 17). Initial liioiminosydnone carbenoids exhibit low nucleophilicity and are thermally unstable. At −80 °C, these substances did not react with active electrophiles such as trimethylsilyl chloride, methyl iodide and allyl bromide, while at higher temperatures they underwent rapid decomposition [48].

Scheme 17. Interaction of sydnone imine carbenoids with aldehydes.

Reaction conditions for the formulation of sydnone imines were studied using different lithium bases followed by reaction with 1-methoxy-N,N-dimethylmethyleneiminium methyl sulfate (Scheme 18) [48]. Metalation with LDA, LiHDMS and nBuLi provides higher yields of aldehydes 29 than Et2NLi. At the same time, reactions of C4-lithiated sydnone imines with DMF as well as direct formulation using the Vielsmeier reagent were unsuccessful.

Scheme 18. Formylation of sydnone imines.

Recently, it was shown that N3-cyclohexyl-C4-lithioiminosydnone can react with aryl isocyanates and isothiocyanates with a formation of the corresponding amides and
thioamides 30 in high yields. However, the same reaction with N^3-aryl-substituted sydnone imines 22 afforded 5-aryldihydradrazono-imidazolidine-2,4-diones or -dithiones 31 and 1,2,4-triazoles 32 in moderate yields (Scheme 19). Reaction conditions, stoichiometric amounts of isocyanates and isothiocyanates and substituent at the N^3 position of the sydnone imine ring were shown to strongly affect the reaction pathway. Generally, utilization of isocyanates instead of isothiocyanates and conducting the reaction at room temperature promoted the formation of 1,2,4-triazoles 32 [49]. Interaction of lithio sydnone imines 22 with tetracyanoethylene afforded pyrazoles as a result of reductive 1,3-dipolar cycloaddition, while the addition of azodicarboxylate gave 4-hydrazinylsydnone imines [50]. A formation of C^4-B and C^4-Hg adducts from carbenoids 22 was also reported [51].

Scheme 19. Interaction of sydnone imine carbenoids 22 with isocyanates and isothiocyanates.

Cycloaddition reactions for mesionic compounds were studied extensively on sydrones and münchnones, while for sydnone imines this process was investigated rarely. A [3+2]-cycloaddition of N^6-derived iminosydnones with several strained alkynes resulted in the formation of pyrazoles and isocyanates (Scheme 20). This method is based on a general concept of bioorthogonal click-and-release reactions [36,38–40,52,53] due to the ability of sydnone imines to remove the mesionic fragment through cycloaddition with alkynyl triggers. It was shown that electron-withdrawing substituents at N^3-aryl iminosydnones and a urea moiety connected to the exocyclic nitrogen atom of the iminosydnone core had a strong beneficial impact on the reaction kinetics. Moreover, sydnone imines bearing azide function have diverse reactivity towards alkynes depending on a structure of dipolarophile, which allows for performing sequential [3+2]-cycloadditions. Bioorthogonal reactions of sulfonyl sydnone imines as prodrugs and dibenzoazacyclooctyne derivatives are served as an efficient tool to release sulfonamide medications under physiological conditions. An extensive and excellent review on the synthetic and biomedical applications of bioorthogonal reactions of sydnone imines and related mesionic compounds was very recently published [54].

Scheme 20. Bioorthogonal reactions of sydnone imines.
A recent example of iminosydnone [3+2]-cycloaddition with unstrained alkyne was revealed in a copper-catalyzed reaction of terminal phenylbutyne and N\(^3\)-phenyl-N\(^6\)-carbamoyl sydnone imine 33 (Scheme 21) [55]. However, heating at 60 °C provided only a moderate yield of cycloaddition-retro-Diels-Alder product 34, attempts to improve the reaction efficiency were unsuccessful.

Scheme 21. Click reaction of sydnone imine 33 with phenylbutyne.

The most studied application of iminosydnones is their capability of exogenous NO release under physiological conditions [56]. Several sydnone imines possessing good NO-donor profiles were discovered as possible drug candidates due to their vasodilating and antihypertensive action. In vivo experiments on various mammals (dogs, cats, rabbits and pigs) showed that N-ethoxycarbonyl-3-morpholinosydnone imine produced a gradually developing and prolonged hypotensive action which was characterized by a decrease in pulse pressure, because of a greater fall in systolic than diastolic pressure. In addition, N-ethoxycarbonyl-3-morpholinosydnone imine was found to be non-toxic to animals in concentrations up to 100 µg/mL [57]. Moreover, several clinically approved iminosydnones, such as Molsidomine, revealed high antiplatelet activity. The platelet-inhibiting effect is presumably associated with direct activation of platelet-soluble guanylate cyclase by SIN-1, the bioactive metabolite of molsidomine [58]. Design and synthesis of a series of sydnone imine amino acids conjugate 35 with regard to the development of peptide-based therapies in medicinal chemistry were also carried out. Prepared sydnone imine amino acids hybrids showed moderate levels of NO release in a glutathione (GST) buffer containing superoxide dismutase (SOD), while similar studies under identical conditions in the absence of GST and SOD gave no significant NO production [59]. Prepared amino acids were shown to be exogenous pro-NO-release compounds that allow for improving the strategy of localization and targeting of NO-delivery. Molecular hybridization of a sydnone imine scaffold with integrin binding aspartic acid-glycine-arginine (RGD) peptide sequence and one of the chemotherapeutic agents, abiraterone, resulted in increased cytotoxic effects against PC3 and MCF7 cancer cell lines [60]. An analogous approach was used for a combination of the iminosydnone motif with known NSAID sulindac which improved antiproliferative and anti-inflammatory properties of the resulted hybrids 36 (Figure 3). These sydnone imine-sulindac conjugates showed promising cytotoxic activity at a concentration of 50 µM, while at lower concentrations (1.0 and 0.5 µM) no measurable cytotoxic effects were detected [61]. Dual acting NO-donor-antioxidant sydnone imine SA-2 bearing 1-hydroxy-2,2,6,6-tetramethylpiperidine moiety revealed an ability to protect photoreceptor cells from H\(_2\)O\(_2\) induced oxidative stress and may promote an intraocular pressure lowering [34]. In addition, sydnone imines demonstrate a number of other pharmacological activities including psychostimulant [62] and antibacterial [63], as well as being found to act as trypanocidal agents [64]. The lethal dose (LD\(_{100}\)) of sydnone imines in Trypanosoma equiperdum was determined to be 25 and 50 µM within 48 h, respectively [64]. Using a combination of molecular docking and molecular dynamics simulations a series of iminosydnone-based insecticides was designed and synthesized [65]. Aside from biomedical applications, sydnone imine derivatives were used as additives or catalysts in Pd-catalyzed cross-coupling reactions [66,67]. Additionally, recently, the first representatives of sydnone imine-based dense energetic materials with high detonation performance were prepared [68].
3. Furoxans

Among the variety of nitrogen–oxygen organic and organometallic compounds capable of NO release under physiological conditions, the furoxan (1,2,5-oxadiazole 2-oxide) scaffold has attracted considerable attention [69–72] mainly due to the high stability of the furoxan cycle under ambient conditions and absence of nitrate tolerance under continuous therapy [23]. Long-term investigations of Prof. Alberto Gasco [73,74] revealed a possibility of regioisomeric furoxans with different positions of the N-oxide group to produce NO in significantly different amounts. Since furoxan isomers 37 and 37′ can be interconverted to each other through dinitrosoethylene intermediate 38 at heating or photoirradiation (Scheme 22), this important feature may lead to the diversity-oriented construction of novel NO-donor drug candidates depending on the structure of furoxan isomer and biological target.

Scheme 22. Mechanism of the furoxan ring isomerization.

The two most promising NO-donor furoxans–CAS 1609 and CHF 2363 (Figure 4)–that possess vasodilating and anti-aggregation properties were discovered in the mid-1990s. CAS 1609 is a strong NO donor, which significantly increases cGMP levels in animal models of pulmonary artery strips and at low doses, decreases blood pressure and left ventricular end-diastolic pressure [75]. Later, our group revealed significant antiaggregant activity of CAS 1609 induced by adenosine diphosphate (ADP) and adrenaline and partially by collagen [76]. Similar cardiovascular properties were displayed by CHF 2363, which exhibits significant NO-release capacity and exerts anti-aggregation and vasodilating activity [77]. At the same time, CAS 1609 displays moderate cytotoxic and genotoxic effects at very high concentrations (1 mM), whereas similar effects of the water-soluble analog of CHF 2363 start to occur at much lower concentrations (5 µM). It was clearly shown that such effects are closely associated with the NO-donor capacity of furoxans by comparison with non-NO-donating furazans, and because both effects are decreased in the presence of the NO scavenger oxyhemoglobin [78].

Figure 4. Structures of CAS 1609 and CHF 2363.
The thiol-dependent mechanism of NO-release from furoxans is now widely accepted, however, details of this process remain uncertain. Since the furoxan ring has a strong electron-withdrawing character, both carbon atoms of this heterocycle are quite electrophilic and are prone to reaction with nucleophiles. Thus, there are two main routes resulting in NO-release from furoxans depending on whether thiolate-anion, generated, for example, from cysteine, attacks C(3) or C(4) atom of the furoxan ring (Scheme 23). Both degradation pathways a and b result in a furoxan ring cleavage with a concomitant release of NO. Recent mechanistic investigations [70] indicate that at least in several particular cases attack of thiolate-anion on the C(3) atom of the furoxan cycle is more favorable. Interestingly, most of the 4-nitrofuroxans do not cleave under the action of thiolate-anions but undergo nucleophilic substitution of the nitro group resulting in stable sulfanylfuroxan derivatives [69].

![Scheme 23. Mechanism of NO release from furoxans.](image)

In recent years, the main efforts of medicinal chemists were directed towards the construction of hybrid drug candidates containing NO-donor furoxan moiety connected to a known pharmaceutical or a potential pharmacophore through an appropriate linker. However, synthetic methodologies toward regio- and chemoselective functionalization of the furoxan ring itself were also developed. In this chapter, both these approaches to the synthesis of pharmacologically active furoxan-based drug candidates are considered. Methods for the synthesis of common functionally substituted furoxans were extensively covered in some previous reviews [69,71].

Recently, a new method for the selective diazotization of the readily available 4-aminofuroxans 39 [79] using NOBF₄ as a mild nitrosating agent was developed [80]. This protocol substantially broadened the scope of furoxanyl diazonium salts 40 which can be isolated in solid-state or undergo subsequent azo coupling with electron-donating arenes or CH-acids [80]. In some cases, utilization of NaNO₂ for diazotization was also suitable [81]. Thus formed arylazofuroxans 41 demonstrated a photoswitching ability: under visible light irradiation E-isomers 41 underwent an isomerization of the N=N bond generating Z-arylazofuroxans 41' (Scheme 24) which are stable under ambient conditions [81]. As for most molecular photoswitches, such isomerization is equilibrium and in this case, the E/Z ratios strongly depend on both substituents at the furoxan ring and N=N bond. At heating Z-isomers 41' smoothly revert to the initial E-arylazofuroxans 41. Importantly, E-isomers 41 released low amounts of NO (<10%), while mixtures of E- and Z-isomers provided significantly higher levels of NO release (33–52%) exceeding that of reference CAS 1609. This feature is rather advantageous, especially since synthesized furoxan-based molecular photoswitches undergo photoisomerization under visible light irradiation to avoid any hazards caused by UV light.
Furoxanyl diazonium salts 40 also underwent in situ reduction to the corresponding hydrazines 42 which could not be isolated due to the highly electrophilic nature of the ring but were trapped with various aldehydes to form previously unknown N-(furoxanyl)hydrazones 43 (Scheme 25) [82]. A utilization of TEBAC as a phase transfer catalyst and Sc(OTf)₃ as a Lewis acid were crucial to increase the rate of the reduction and to avoid degradation of highly reactive diazonium salts 40. A synthesized library of furoxan-based compounds represents an isosteric replacement of described drug candidates for the treatment of various neglected diseases including tuberculosis, leishmaniosis, schistosomiasis, and Chagas’ disease [83–86].

A series of hetarylfuroxans was synthesized through cyclocondensation of bromoacetyl-furoxans 44 with various binucleophiles [87–89]. In particular, a regioselective condensation of substrates 44 with thiosemicarbazide afforded hydrazinylthiazoles 45 which underwent in situ reaction with aldehydes resulting in a formation of the corresponding hydrazones 46 (Scheme 26). Compounds 46 showed moderate cytotoxic activity against two human cancer cell lines A549 and HCT116 [90].

Recently, a novel reactivity pattern of furoxans based on their radical functionalization was established (Scheme 27). It was found that alkyl radicals generated from carboxylic acids in mild conditions add to the C(3) carbon atom of the furoxan ring in corresponding bromo or arylsulfonyl derivatives 47 followed by elimination of functional moiety and formation of target products 48 [91,92]. This protocol enables wide opportunities for the design of pharmacologically oriented furoxan-based compounds. However, it requires utilization of aliphatic carboxylic acids, while in the case of benzoic or heteroaromatic carboxylic acids target furoxans are formed in very low yields. At the same time, such methodology was also useful for the C-B bond formation directly on the furoxan ring for the synthesis of previously unknown borylfuroxans 49. Using this approach, various N-heterocyclic carbene (NHC) moieties (imidazole, benzimidazole, 1,2,4-triazole and pyridine) were successfully installed via BH₂ linkage [93].
A number of hybrid drug candidates comprising of a known pharmacologically active scaffold linked to the furoxan ring directly or via an appropriate spacer were synthesized from bromomethyl- or (phenylsulfonyl)furoxans using a nucleophilic substitution reaction. For example, an interaction of 3-bromomethyl-4-methylfuroxan \(50a\) with amino acid-functionalized betulonic acid derivatives afforded hybrid compounds \(51\), which showed moderate anti-inflammatory activity. Advantageously, most of the synthesized hybrids were non-toxic (GI\(_{50}\) > 100 µM) according to the MTT test against immortalized human fibroblasts, while reference drug doxorubicin possessed high toxicity (GI\(_{50}\) > 3.15 µM) under the same conditions [94]. The analogous reaction of 4-aryl-3-bromomethylfuroxans \(50b\) with spiro[isoquinoline-4,4'-]piperidine derivative resulted in a formation of the tricyclic compounds \(52\) (Scheme 28). All synthesized hybrids \(52\) demonstrated moderate to good vasodilating and antioxidant properties, while structures containing \(o\)-nitro- or \(o\)-methoxyphenyl substituents at the furoxan ring were moderate phosphodiesterase 5 (PDE 5) inhibitors as compared to the known pharmaceutical Sildenafil [95].

Nucleophilic substitution of the mesyloxy moiety in furoxans \(53\) with rutaecarpine derivatives afforded a series of hybrid structures \(54\) (Scheme 29). Rutaecarpine is a quinazolinocarboline-type alkaloid which is a major bioactive constituent in Evodiae Fructus prescribed for treatment of hypertension in traditional Chinese medicine. Molecular hybridization of this alkaloid with a furoxan subunit resulted in a more potent vasodilator and antihypertensive effect of the prepared hybrids at various dosages (20–40 mg/kg) in vivo in rats compared to parent medication [96].
Scheme 29. Synthesis of furoxan–rutaecarpine hybrids.

Due to the high electron-withdrawing nature of the furoxan ring, the SNAr process is a quite versatile reaction in furoxan chemistry. As a rule, bis(phenylsulfonyl)furoxan 55 is used as a starting material for numerous transformations. Since C(4) carbon atom of the furoxan ring is much more electrophilic than C(3) atom, 4-PhSO₂ moiety in compound 55 displaced completely selectively in reactions with nucleophiles. For example, the tandem nucleophilic substitution of a phenylsulfonyl group in furoxan 55 under the action of phenolic aldehydes with subsequent condensation of formyl group in compounds 56a–c with isonicotinic hydrazide afforded a series of hybrids 57a–c, which are considered as promising agents active against Mycobacterium tuberculosis (Scheme 30). Moreover, there is a direct correlation between NO-donor capability and antitubercular activity: the more powerful NO-donor hybrid among the series is the most active antitubercular agent [97]. Further in-depth studies revealed that compounds 57b,c showed no mutagenicity and were active against both mono- and multidrug-resistant tuberculosis strains. In addition, treatment with furoxans 57b,c led to undetectable levels of the bacterium in the lungs of mice while no standard drugs have shown this advantageous effect. Oral administration of furoxans to mice at 20 mg/kg dosage had no effect on behavioral parameters (Hippocratic screening) and did not damage the liver and kidneys according to the histopathology analysis [98].

Scheme 30. Synthesis of furoxan–hydrazone hybrids 57 linked via phenol bridge.

A combination of NO-donor furoxan scaffold with anticancer drugs may serve as a promising tool to overcome the problem of multidrug resistance. A tumor-specific NO-release system comprising of 10-hydroxycamptothecin (HCPT)-loaded charge-reversal chitosan nanoparticles and covalently linked phenylsulfonylfuroxan on the surface was
recently designed. In vitro studies proved that such a system significantly enhanced cellular uptake at pH 6.5 and immensely reduced the expression of P-glycoprotein, which was in favor of increasing killing ability against MCF-7/ADR cancer cells. Furthermore, in vivo studies confirmed that the resultant system precisely released NO in the tumor and scarcely released NO during blood circulation, avoiding NO poisoning [99].

Due to a known chelating effect of the 8-hydroxyquinoline scaffold and its potential in cancer treatment, a series of furoxan–hydroxyquinoline hybrids 58 and 59 were synthesized through a two-step procedure. Bis(phenylsulfonyl)furoxan 55 was converted into amines 60 which underwent coupling with 8-hydroxyquinoline-based carboxylic acids (Scheme 31). Thus obtained conjugates possessed good antiproliferative activity against various cancer lines and showed good metal chelation and NO-releasing abilities. Synthesized hybrid structures demonstrated a synergistic effect caused by the presence of the furoxan motif: at the same dose of 20 mg/kg in mice, the tumor inhibition rate of a lead hybrid was 61.8% compared to 44.7% for the parent 8-hydroxyquinoline [100]. A number of various hybrid drug candidates comprising of a furoxan motif and other pharmaceutical scaffolds (estradiol [101], rhodamine B [102], triptolide [103]) were also prepared starting from bis(phenylsulfonyl)furoxan and these compounds showed promising anticancer and anti-inflammatory properties.

Scheme 31. Synthesis of furoxan–hydroxyquinoline prochelator hybrids.

A series of anticancer Pt complexes bearing a NO-donor furoxan subunit was synthesized (Figure 5). Compound 61 is a cisplatin prodrug, which releases it directly in cells along with NO. Such a dual role of hybrid 61 provides a synergistic effect on the inhibition of tumor growth which is demonstrated both by higher potency and lower systemic toxicity in comparison with parent cisplatin. Pt–furoxan derivatives did not alter the growth of mice in both dosages, suggesting the low toxicity of drug candidates. By comparison, cisplatin clearly decreased the bodyweight of mice, and even one mouse died during the treatment of cisplatin (1–2 mg/kg dosages were used) [104]. Other Pt-organic complexes may serve as a potential replacement for cisplatin and oxoplatin. The anti-cancer effect of 62a–e was attributed to their interaction with DNA, which formed Pt/DNA adducts responsible for cytotoxicity [105].
Hybrid structures 63 and 64 comprising of the furoxan motif and glycolic or acetylsalicylic (aspirin) acids scaffolds were synthesized (Scheme 32). Both compounds revealed high antiplatelet activity which was comparable to that of the previously investigated CAS 1609. In addition, these structures possess a selective mechanism of inhibition of platelets aggregation mediated by ADP and adrenaline but not ristocetin, collagen and arachidonic acid and their antiplatelet effects are mainly independent of the NO action [106].

Several approaches to the functionalization of pharmacologically relevant benzofuroxans were also developed. Coupling of benzofuroxancarboxylic acid with pharmacophoric...
amines afforded a series of corresponding amides, in which a thiomorpholine derivative revealed an excellent antibacterial activity against drug-resistant strains of Mycobacterium tuberculosis [107]. Tri- and tetracyclic ring systems incorporating a nitrofuroxanoquinoline scaffold revealed extraordinary high NO-donor ability which may be useful for a search of novel drug candidates in this series [108]. Benzofuroxans bearing additional electron-withdrawing groups are also considered as super-electrophiles which is convenient for rapid and straightforward installation of various pharmacophoric moieties to the benzofuroxan core. Recently, a thorough investigation of the reactivity of 4,6-dichloro-5-nitrobenzofuroxan with aliphatic and aromatic amines was performed [109]. Using a super-electrophilic nature of the benzofuroxan ring system, a series of promising anticancer drug candidates 65 bearing 2-aminothiazole moiety was synthesized (Scheme 33). The cytotoxic activity of the lead benzofuroxan derivative bearing 4-methoxyphenyl substituent at the aliphatic nitrogen atom was attributed to induction of apoptosis in m-HeLa cells at early stages (10.7–17.3% of apoptotic cells were observed using 50–100 µM concentrations) [110].

![Scheme 33. Synthesis of benzofuroxan–aminothiazole hybrids.](image)

A number of other furoxan derivatives also displayed a wide range of pharmacological activities. For example, 3-cyano- and 3-nitro-4-phenylfuroxans revealed promising antiplatelet activity [111], while the latter compound also inhibited Pseudomonas aeruginosa PAO1 growth and prevented PAO1 biofilm formation [112]. Several furoxan–peptide hybrids also demonstrated antimicrobial activity against Staphylococcus aureus and Escherichia coli biofilm formation [113]. A highly potent drug candidate PRG150 (3-methylfuroxan-4-carbaldehyde) is considered as a novel analgesic for the effective treatment of painful diabetic neuropathy. PRG150 is useful for relieving mechanical allodynia, a defining symptom of neuropathic pain, as was shown in a rat model of painful diabetic neuropathy [114]. The metabolic stability and biodistribution of PRG150 using positron emission tomography and 11C- and 13N-labeled pharmaceutical demonstrated a higher uptake of the 13N isotope over 11C in the spinal cord, which indicates a key role of NO release in the somatosensory nervous system responsible for the analgesic effect of PRG150 [115]. Subsequent in-depth studies confirmed a role for NO in the treatment of painful diabetic neuropathy since the cellular effects of PRG150 on forskolin-stimulated cyclic adenosine monophosphate (cAMP) responses in vitro and in vivo were transduced through the modulation of µ-opioid receptor signaling [116]. Recently, a biomedical application of diacylfuroxans as precursors to nitrite oxides capable of covalent inhibition of glutathione peroxidase 4 (GPX4) to induce ferroptosis was revealed [117]. Application of furoxan-based compounds as high-energy materials, primary or secondary explosives, propellants or rocket fuels was also reported numerous [118–122].

4. Pyridazine Dioxides and Azasydnones

The final chapter of the present review covers several aspects of the synthesis and biomedical applications of two rather neglected heterocyclic subclasses: pyridazine dioxides and azasydnones (1,2,3,4-oxatriazolium-5-olates). Historically, both these heterocyclic derivatives are known as exogenous NO-donors for more than 30 years [27]. However,
substrate-specific and harsh methods for their synthesis significantly restricted in-depth investigation of their functional properties. Nevertheless, recent achievements of several research groups provided some solutions to this problem and modern convenient synthetic protocols to an assembly of both pyridazine dioxide and azasydnone frameworks along with their application potential are summarized in this section.

Direct oxidation of pyridazines 66 with peracetic or pertrifluoroacetic acid proceeds with poor yields of the corresponding dioxides 67 [123]. Recently, a more effective oxidation method using one of the strongest oxidizers HOF was developed (Scheme 34). However, significant amounts of pyridazine mono-N-oxides were also formed [124].

Scheme 34. Direct oxidation of pyridazines.

A more convenient approach toward the formation of the pyridazine dioxide scaffold is based on an oxidative cyclization of 1,4-dioximes 68. This method is more efficient and provides high yields of target heterocyclic NO-donors 69 including those comprised of a pyridazine dioxide motif fused with other heterocyclic rings (pyrazole [125], furazan [126], furoxan [127,128]) (Scheme 35). Initially, PhI(OAc)₂ [129] or Pb(OAc)₄ [130,131] were used as oxidants, but later N₂O₄ [125,126,128] or HNO₃ [127] were shown to provide higher yields and purity of pyridazine dioxides 69.

Scheme 35. Oxidative cyclization of 1,4-dioximes.

Aryl substituted 2H-pyrazolo[3,4-d]pyridazine 5,6-dioxides produced low amounts of NO (4.2–10.5%), while those bicyclic derivatives comprising of NO-donor furoxan and pyridazine dioxide subunits demonstrated the highest NO-releasing ability (27.7–48.3%) [125]. Furthermore, 4,7-dimethyl-1,2,5-oxadiazolo[3,4-d]pyridazine 1,5,6-trioxide was able to relax noradrenaline-precontracted aortic rings at concentrations less than 0.1 mM. Deoxygenated furazan analog was less active since the furazan subunit is unable to release NO. Nevertheless, both these compounds significantly increased cGMP levels in aortic rings and platelets and exhibited promising antiaggregant activity [132]. Unfortunately, the mechanism of NO release from pyridazine 5,6-dioxides is unknown so far.

Azasydrones 70 are usually constructed by azo coupling of tailor-made or generated in situ arene/hetarene diazonium salts with bromonitromethane with subsequent oxidative [133] or thermal [36] cyclization of the corresponding hydrazones 71. Recently, our group proposed a more convenient one-pot approach using potassium nitroformate and catalytic amounts of ZnCl₂ which enabled a straightforward assembly of the azasydnone ring (Scheme 36) [134].
Due to pronounced NO-releasing properties, azasydnones possess promising antihypertensive activity and low toxicity [135,136]. In addition, (1,2,5-oxadiazolyl)azasydnones showed excellent antiplatelet activity in the case of ADP and adrenaline used as inducers completely suppressing the formation of the aggregates, which is rather a unique feature. Importantly, (1,2,5-oxadiazolyl)azasydnones possess a selective mechanism of inhibition of platelets aggregation mediated only by ADP and adrenaline, which are considered to be the main agents causing thrombus formation [137]. Additionally, recently, some energetic applications of azasydnones were reported [138–141].

Mechanistic investigations on NO-donating properties of azasydnones revealed their ability to release NO at pH > 6 either in vitro or enzymatically. This process includes nucleophilic cleavage of the azasydnone ring followed by stepwise degradation of formed nitrosamines (Scheme 37). Degradation of (1,2,5-oxadiazolyl)azasydnones afforded benzoic acid as a main decomposition product due to the concomitant cleavage of the 1,2,5-oxadiazole ring. Since benzoic acid is also non-toxic for living organisms, (1,2,5-oxadiazolyl) azasydnones are considered advantageous in future drug design [137].

5. Conclusions and Future Outlooks

Synthesis and reactivity of heterocyclic NO-donors have become one of the urgent areas of research in organic and medicinal chemistry. In comparison to clinically used organic nitrates, heterocyclic scaffolds capable of NO release under physiological conditions are more advantageous due to hydrolytic stability and improved pharmacological profiles. Aside from studying biomedical applications of simple heterocyclic NO-donors, numerous efforts were directed towards the construction of hybrid pharmaceuticals incorporating NO-donor heterocyclic subunits as a key structural fragment to advance the pharmacological profile of the parent drug. To realize the hybridization approach, a number of modern synthetic methodologies involving preliminary functionalization of the heterocyclic ring with subsequent hybridization with an appropriate pharmacophore were utilized. This approach is very promising for the construction of novel multifunctional drugs to overcome the significant problem of multidrug resistance. In general, diversification of the
heterocyclic NO-donor scaffold has become a reliable tool in modern organic chemistry; therefore, the creation of novel pharmacologically active lead hybrids with NO-donor properties should be expected in near future.

In this review, recent advances in the synthesis, reactivity and pharmacological activity of the main NO-donor heterocyclic subclasses are summarized. Although the structures of considered nitrogen–oxygen molecular systems are quite similar, synthetic methods for their preparation and functionalization differ significantly. The synthesis of sydnone imines and furoxans was extensively studied and nowadays main trends are directed toward selective functionalization of these heterocycles. Furthermore, incorporation of the sydnone imine or furoxan motif in the structure of known pharmaceutical or promising drug candidates was found to be fruitful in search of novel pharmacologically active and non-toxic substances. In addition, sydnone imines are highly valuable substrates for bioorthogonal chemical reactions, which are of major importance in the field of chemical biology. On the contrary, the chemistry of pyridazine dioxides and azasydnones is explored to a lesser extent since both these heterocyclic subunits were hard to construct. Nevertheless, recently developed novel and convenient methods for the assembly of pyridazine dioxides and azasydnones will encourage further investigations on the pharmacological activity of these compounds. Overall, each type of considered heterocyclic NO-donors has a strong potential in medicinal chemistry and drug design and we hope that the present review will stimulate future research in this field.

Author Contributions: Writing—review and editing, L.L.F. and E.S.Z.; supervision, L.L.F.; project administration, L.L.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Vanhoutte, P.M.; Zhao, Y.; Xu, A.; Leung, S.W.S. Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of the Endothelium-Derived Vasodilator Mediator. *Circ. Res.* 2016, 119, 375–396. [CrossRef] [PubMed]
2. Yang, Y.; Huang, Z.; Li, L.-L. Advanced nitric oxide donors: Chemical structure of NO drugs, NO nanomedicines and biomedical applications. *Nanoscale* 2021, 13, 444–459. [CrossRef] [PubMed]
3. Paulo, M.; Costa, D.E.F.R.; Bonaventura, D.; Lunardi, C.N.; Bendhack, L.M. Nitric Oxide Donors as Potential Drugs for the Treatment of Vascular Diseases Due to Endothelium Dysfunction. *Curr. Pharm. Des.* 2020, 26, 3748–3759. [CrossRef] [PubMed]
4. Gkaliagkousi, E.; Ritter, J.; Ferro, A. Platelet-Derived Nitric Oxide Signaling and Regulation. *Circ. Res.* 2007, 101, 654–662. [CrossRef] [PubMed]
5. Krol, M.; Kepinska, M. Human Nitric Oxide Synthase—Its Functions, Polymorphisms, and Inhibitors in the Context of Inflammation, Diabetes and Cardiovascular Diseases. *Int. J. Mol. Sci.* 2021, 22, 56. [CrossRef] [PubMed]
6. Calabrese, V.; Mancuso, C.; Calvani, M.; Rizzarelli, E.; Butterfield, D.A.; Giuffrida Stella, A.M. Nitric oxide in the central nervous system: Neuroprotection versus neurotoxicity. *Nat. Rev. Neurosci.* 2007, 8, 766–775. [CrossRef]
7. Furchgott, R.F. Endothelium-Derived Relaxing Factor: Discovery, Early Studies, and Identification as Nitric Oxide (Nobel Lecture). *Angew. Chem. Int. Ed.* 1999, 38, 1870–1880. [CrossRef] [PubMed]
8. Ignarro, L.J. Nitric Oxide: A Unique Endogenous Signaling Molecule in Vascular Biology (Nobel Lecture). *Angew. Chem. Int. Ed. 1999, 38, 1882–1892. [CrossRef] [PubMed]
9. Murad, F. Discovery of Some of the Biological Effects of Nitric Oxide and Its Role in Cell Signaling (Nobel Lecture). *Angew. Chem. Int. Ed. 1999, 38, 1856–1868. [CrossRef]
10. Khan, F.H.; Dervan, E.; Bhattacharyya, D.D.; McAuliffe, J.D.; Miranda, K.M.; Glynn, S.A. The Role of Nitric Oxide in Cancer: Master Regulator or NOT? *Int. J. Mol. Sci.* 2020, 21, 9393. [CrossRef]
11. Heinrich, T.A.; da Silva, R.S.; Miranda, K.M.; Switzer, C.H.; Wink, D.A.; Fukuto, J.M. Biological nitric oxide signalling: Chemistry and terminology. *Br. J. Pharmacol.* 2013, 169, 1417–1429. [CrossRef]
12. Basudhar, D.; Ridnour, L.A.; Cheng, R.; Kesavratha, A.H.; Heinecke, J.; Wink, D.A. Biological signaling by small inorganic molecules. *Coord. Chem. Rev.* 2016, 306, 708–723. [CrossRef]
13. Majumder, S.; Sinha, S.; Siamwala, J.H.; Muley, A.; Seerapu, H.R.; Kolluru, G.K.; Veeriah, V.; Nagarajan, S.; Sridhara, S.R.C.; Priya, M.K.; et al. A comparative study of NONOate based NO donors: Spermine NONOate is the best suited NO donor for angiogenesis. Nitric Oxide 2014, 36, 76–86. [CrossRef] [PubMed]

14. Behera, J.; Nagarajan, S.; Saran, U.; Kumar, R.; Keshri, G.K.; Suryakumar, G.; Chatterjee, S. Nitric oxide restores peripheral blood mononuclear cell adhesion against hypoxia via NO-cGMP signaling. Cell Biochem. Funct. 2020, 38, 319–329. [CrossRef]

15. Swaminathan, A.; Kasiviswanathan, D.; Balaguru, U.M.; Kolluru, G.K.; Suryakumar, G.; Chatterjee, S. Hypoxia perturbs endothelium by re-organizing cellular actin function: Nitric oxide offers limited protection. Tissue Cell 2018, 50, 114–124. [CrossRef]

16. Siamwala, J.H.; Kumar, P.; Veeriah, V.; Muley, A.; Rajendra, S.; Konnikat, S.; Majumder, S.; Mani, K.P.; Chatterjee, S. Nitric Oxide Reverses the Position of the Heart during Embryonic Development. Int. J. Mol. Sci. 2019, 20, 1157. [CrossRef]

17. Kumar, P.; Sundaresan, L.; Chatterjee, S. Nitrative Stress and Cardiogenesis: Cardiac Remodelling Perturbs Embryonic Metabolome. In Modulation of Oxidative Stress in Heart Disease; Chakraborti, S., Dhalli, N.S., Dikshit, M., Ganguly, N.K., Eds.; Springer: Singapore, 2019; pp. 377–392.

18. Giri, S.; Thakar, S.; Majumder, S.; Chatterjee, S. Regulation of Oxidative Stress by Nitric Oxide Defines Lung Development and Diseases. In Oxidative Stress in Lung Diseases; Chakraborti, S., Parinandi, N.L., Ghosh, R., Kang, N.K., Chakraborti, T., Eds.; Springer: Singapore, 2019; pp. 445–464.

19. Serafim, R.A.M.; Pernichelle, F.G.; Ferreira, E.I. The latest advances in the discovery of nitric oxide hybrid drug compounds. Expert Opin. Drug. Discov. 2017, 12, 941–953. [CrossRef] [PubMed]

20. Bryan, N.S. Natural Product Chemistry for Nitric Oxide Based Therapeutics. Isr. J. Chem. 2019, 59, 414–419. [CrossRef]

21. Huang, Z.; Fu, J.; Zhang, Y. Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. J. Med. Chem. 2017, 60, 7617–7635. [CrossRef]

22. Wang, P.G.; Xian, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, A.J. Nitric Oxide Donors: Chemical Activities and Biological Applications. Chem. Rev. 2002, 102, 1091–1134. [CrossRef] [PubMed]

23. Gasco, A.; Schoenafinger, K. Nitric Oxide Donors: For Pharmaceutical and Biological Applications; Wang, P.G., Cai, T.B., Taniguchi, N., Eds.; Wiley-VCH: Weinheim, Germany, 2005; pp. 131–175.

24. Bath, P.M.W.; Krishnan, K.; Appleton, J.P. Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review). Cochrane Database Syst. Rev. 2017, 4, CD003998.

25. Steven, S.; Oelze, M.; Hausding, M.; Roohani, S.; Kashani, F.; Kröller-Schön, S.; Helmstädter, J.; Jansen, T.; Baum, C.; Iglarz, M.; et al. Oxidative Stress and Cardiovascular Dysfunction: From Basic Science to Applied Investigations. Oxid. Med. Cell. Longevity 2018, 2018, 7845629.

26. Kuchurov, I.V.; Arabadzhi, S.S.; Zharkov, M.N.; Fershtat, L.L.; Zlotin, S.G. Sustainable Synthesis of Polynitroesters in the Freon Medium and their in Vitro Evaluation as Potential Nitric Oxide Donors. ACS Sustain. Chem. Eng. 2016, 8, 2535–2540. [CrossRef]

27. Schönafinger, K. Heterocyclic NO prodrugs. II Phamacove 1999, 54, 316–320. [CrossRef]

28. Feelisch, M.; Ostrowski, J.; Noack, E. On the mechanism of NO release from sydnonimines. Bioorg. Med. Chem. Lett. 2017, 27, 54–58. [CrossRef] [PubMed]

29. Ullrich, T.; Oberle, S.; Abate, A.; Schröder, H. Photoactivation of the nitric oxide donor SIN-1. FEBS Lett. 1997, 406, 66–68. [CrossRef]

30. Cherepanov, I.A.; Moiseev, S.K. Recent developments in the chemistry of sydnone and syndine imines. Adv. Heterocycl. Chem. 2020, 131, 49–164.

31. Beal, E.N.; Tumbull, K. An efficient, one-pot synthesis of 3-alkyl or aryl syndine imines. Synth. Commun. 1992, 22, 673–676. [CrossRef]

32. Gotz, M.; Grozinger, K. 3-Hydroxysydnone imines. Tetrahedron 1971, 27, 4449–4456. [CrossRef]

33. Cherepanov, I.A.; Samarskaya, A.S.; Godovikov, I.A.; Lyssenko, K.A.; Pankratova, A.A.; Kalinin, V.N. Nα-tert-Butoxycarbonyl derivatives of sydnone imines: Preparation and synthetic use. Tetrahedron Lett. 2018, 59, 727–729. [CrossRef]

34. Acharya, S.; Rogers, P.; Krishnamoorthy, R.R.; Stankowska, D.L.; Dias, H.V.R.; Yorio, T. Design and synthesis of novel hybrid sydnone imines and prodrug use for glaucomatous optic neuropathy. Bioorg. Med. Chem. Lett. 2016, 26, 1490–1494. [CrossRef]

35. Cai, T.B.; Lu, D.; Tang, X.; Zhang, Y.; Landerholm, M.; Wang, P.G. New glycosidase activated nitric oxide donors: Glycose and 3-morpholinosydnone conjugates. J. Org. Chem. 2005, 70, 3518–3524. [CrossRef] [PubMed]

36. Bernard, S.; Audisio, D.; Riomet, M.; Bregant, S.; Wallstrau, A.; Plougastel, A.; Decuytere, E.; Gabriell, S.; Kumar, R.A.; Elyian, J.; et al. Bioorthogonal Click and Release Reaction of Iminosydones with Cycloalkynes. Angew. Chem., Int. Ed. 2017, 56, 15612–15616. [CrossRef]

37. Samarskaya, A.S.; Cherepanov, I.A.; Godovikov, I.A.; Kalinin, V.A. Nα-α-haloacetyl syndine imine derivatives. Dokl. Chem. 2015, 463, 199–203. [CrossRef]

38. Shao, Z.; Liu, W.; Tao, H.; Liu, F.; Zeng, R.; Champagne, P.A.; Cao, Y.; Houk, K.N.; Liang, Y.; Cao, Y.; et al. Bioorthogonal release of sulfonamides and mutually orthogonal liberation of two drugs. Chem. Commun. 2018, 54, 14089–14092. [CrossRef] [PubMed]

39. Riomet, M.; Decuytere, E.; Porte, K.; Bernard, S.; Plougastel, L.; Kolodych, S.; Audisio, D.; Taran, F. Design and Synthesis of Iminosydones for Fast Click and Release Reactions with Cycloalkynes. Chem. Eur. J. 2018, 24, 8535–8541. [CrossRef]

40. Riomet, M.; Porte, K.; Madegard, L.; Thuéry, P.; Audisio, D.; Taran, F. Access to N-Carbonyl Derivatives of Iminosydones by Carbonylimidazolodiazirine Activation. Org. Lett. 2020, 22, 2403–2408. [CrossRef] [PubMed]
94. Popov, S.A.; Semenova, M.D.; Baev, D.S.; Sorokina, I.V.; Zhukova, N.A.; Frolova, T.S.; Tolstikova, T.G.; Shultz, E.E.; Turks, M. Lupane-type conjugates with aminoc acids, 1,3,4-oxadiazole and 1,2,5-oxadiazole-2-oxo derivatives: Synthesis, anti-inflammatory activity and in silico evaluation of target affinity. Steroids 2019, 150, 108443. [CrossRef]

95. Prabhuling, S.; Tamboli, Y.; Choudhari, P.B.; Bhatia, M.S.; Mohanta, T.K.; Al-Harrasi, A.; Pudukulathan, Z.K. Synthesis and Modeling Studies of Furoxan Coupled Spiro-Isoquinolino Piperidine Derivatives as NO Releasing PDE 5 Inhibitors. Biomedicines 2020, 8, 121. [CrossRef]

96. Ma, J.; Chen, L.; Fan, J.; Cao, W.; Zeng, G.; Wang, Y.; Li, Y.; Zhou, Y.; Deng, X. Dual-targeting Rutacearpine-NO donor hybrids as novel antiherpertensive agents by promoting release of CGRP. Eur. J. Med. Chem. 2019, 168, 146–153. [CrossRef]

97. Dos Santos Fernandes, G.F.; Souza, P.C.; Marino, L.B.; Chegaev, K.; Guglielmo, S.; Lazzarato, L.; Fruttero, R.; Chung, M.C.; Pavan, F.R.; dos Santos, J.L. Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis. Eur. J. Med. Chem. 2016, 123, 523–531. [CrossRef]

98. De Souza, P.C.; Fernandes, G.F.S.; Marino, L.B.; Ribeiro, C.M.; da Silva, P.B.; Chorilli, M.; Silva, C.S.P.; Resende, F.A.; Solcia, M.C.; de Grandis, R.A.; et al. Furoxan derivatives demonstrated in vivo efficacy by reducing Mycobacterium tuberculosis to undetectable levels in a mouse model of infection. Biomed. Pharmacother. 2020, 130, 110592. [CrossRef]

99. Niu, X.; Cao, J.; Zhang, Y.; Gao, X.; Cheng, M.; Liu, Y.; Wang, W.; Yuan, Z. A glutathione responsive nitric oxide release system based on charge-reversal chitosan nanoparticles for enhancing synergistic effect against multidrug resistance tumor. NanoMed. Nanotechnol. 2019, 20, 102015. [CrossRef] [PubMed]

100. Zhang, Y.; Yang, J.; Meng, T.; Qin, Y.; Li, T.; Fu, J.; Yin, J. Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents. Eur. J. Med. Chem. 2021, 212, 113153. [CrossRef] [PubMed]

101. Wan, Q.; Deng, Y.; Huang, Y.; Yu, Z.; Wang, C.; Wang, K.; Dong, J.; Chen, Y. Synthesis and Antitumor Evaluation of Novel Hybrids of Phenylsulfonylfuroxan and Estradiol Derivatives. ChemistryOpen 2020, 9, 176–182. [CrossRef] [PubMed]

102. Sodano, F.; Gazzano, E.; Rolando, B.; Marini, E.; Lazzarato, L.; Fruttero, R.; Riganti, C.; Gasco, A. Tuning NO release of organelle-targeted furoxan derivatives and their cytotoxicity against lung cancer cells. Bioorg. Chem. 2021, 111, 104911. [CrossRef] [PubMed]

103. Zang, Y.; Lai, F.; Fu, J.; Li, C.; Ma, J.; Chen, C.; Liu, K.; Zhang, T.; Chen, X.; Zhang, D. Novel nitric oxide-releasing derivatives of triptolide as anti-tumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies. Eur. J. Med. Chem. 2020, 190, 112079. [CrossRef]

104. Dai, Y.; Zhu, Y.; Cheng, J.; Shen, J.; Huang, H.; Liu, M.; Chen, Z.; Liu, Y. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells. Chem. Commun. 2020, 56, 14051. [CrossRef]

105. Zhao, J.; Gou, S.; Sun, Y.; Fang, L.; Wang, Z. Antitumor Platinum(II) Complexes Containing Platinum-Based Moieties of Present Platinum Drugs and Furoxan Groups as Nitric Oxide Donors: Synthesis, DNA Interaction, and Cytotoxicity. Inorg. Chem. 2012, 51, 10317–10324. [CrossRef] [PubMed]

106. Larin, A.A.; Fershtat, L.L.; Ustyuzhanina, N.E.; Gening, M.L.; Nifantiev, N.E.; Makhova, N.N. New hybrid furoxan structures with antiaggregant activity. Mendelev Commun. 2018, 28, 595–597. [CrossRef]

107. Fernandes, G.F.S.; Campos, D.L.; da Silva, I.C.; Prates, J.L.B.; Pavan, A.R.; Pavan, F.R.; dos Santos, J.L. Benzo(furoxan Derivatives as Potent Agents against Multidrug-Resistant Mycobacterium tuberculosis. ChemMedChem 2021, 16, 1268–1282. [CrossRef] [PubMed]

108. Fedik, N.S.; Kletskii, M.E.; Burov, O.N.; Lisovin, A.V.; Kurbatov, S.V.; Chistyakov, V.A.; Morozov, P.G. Comprehensive study of nitrofuroxanoquinolines. New prospective donors of NO molecules. Nitric Oxide 2019, 93, 15–24. [CrossRef] [PubMed]

109. Chugunova, E.; Micheletti, G.; Telese, D.; Boga, C.; Islamov, D.; Usachev, K.; Burilov, A.; Tulesanova, A.; Voloshina, A.; Lyubina, A.; et al. Novel Hybrid Compounds Containing Benzoferoxan and Aminoazhiole Scaffolds: Synthesis and Evaluation of Their Anticancer Activity. Int. J. Mol. Sci. 2021, 22, 7497. [CrossRef]

110. Ustyuzhanina, N.E.; Fershtat, L.L.; Gening, M.L.; Nifantiev, N.E.; Makhova, N.N. New insight into the antiaggregant activity of furoxans. Mendelev Commun. 2016, 26, 513–515. [CrossRef]

111. Orlandi, V.T.; Bolognese, F.; Rolando, B.; Guglielmo, S.; Lazzarato, L.; Fruttero, R. Anti-Pseudomonas activity of 3-nitro-4-phenylfuroxan. Microbiology 2018, 164, 1557–1566. [CrossRef]

112. Fei, Y.; Wu, J.; An, H.-W.; Zhu, K.; Peng, B.; Cai, J.; Zhang, Y.; Li, L.-L.; Wang, H.; Huang, Z. Identification of New Nitric Oxide-Donating Peptides with Dual Biofilm Eradication and Antibacterial Activities for Intervention of Disease-Related Infections. J. Med. Chem. 2020, 63, 9127–9135. [CrossRef]

113. Huang, L.Y.; Tsui, D.Y.; Williams, C.M.; Wyse, B.D.; Smith, M.T. The furoxan nitric oxide donor, PRG150, evokes dose-dependent analgesia in a rat model of painful diabetic neuropathy. Clin. Exp. Pharmacol. Physiol. 2015, 42, 921–929. [CrossRef] [PubMed]

114. Pippin, A.B.; Arshad, Z.H.M.; Voll, R.J.; Nye, J.A.; Ghassabian, S.; Williams, C.M.; Mancini, A.; Liotta, D.C.; Smith, M.T.; Goodman, M.M. In Vitro Metabolic Stability and in Vivo Biodistribution of 3-Methyl-4-furoxancarboxaldehyde Using PET Imaging in Rats. ACS Med. Chem. Lett. 2016, 7, 563–567.

115. Huang, L.; Wyse, B.D.; Williams, C.M.; Smith, M.T. Nitric oxide modulates µ-opioid receptor function in vitro. Clin. Exp. Pharmacol. Physiol. 2019, 46, 676–685. [CrossRef]
